Institutional investors purchased a net $6.0 million shares of THRX during the quarter ended March 2014. This may signal that the smart money is gaining interest in this company as the 79.20% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
TRADEWORX, INC. Bought 10.3 Thousand shares of Theravance Inc
CREDIT SUISSE AG Bought 3.2 Thousand shares of Theravance Inc
QUANTBOT TECHNOLOGIES LLC Bought 1.4 Thousand shares of Theravance Inc